GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adlai Nortye Ltd (NAS:ANL) » Definitions » Marketable Securities

ANL (Adlai Nortye) Marketable Securities : $0.01 Mil (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Adlai Nortye Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Adlai Nortye's Marketable Securities for the quarter that ended in Dec. 2024 was $0.01 Mil.

Adlai Nortye's annual Marketable Securities declined from Dec. 2022 ($21.29 Mil) to Dec. 2023 ($7.01 Mil) and declined from Dec. 2023 ($7.01 Mil) to Dec. 2024 ($0.01 Mil).

Adlai Nortye Marketable Securities Historical Data

The historical data trend for Adlai Nortye's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adlai Nortye Marketable Securities Chart

Adlai Nortye Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Marketable Securities
53.81 21.29 7.01 0.01

Adlai Nortye Quarterly Data
Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23 Jun24 Dec24
Marketable Securities Get a 7-Day Free Trial Premium Member Only - 0.01 7.01 0.01 0.01

Adlai Nortye Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Adlai Nortye  (NAS:ANL) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Adlai Nortye Marketable Securities Related Terms

Thank you for viewing the detailed overview of Adlai Nortye's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Adlai Nortye Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adlai Nortye Ltd (NAS:ANL) » Definitions » Marketable Securities
Comparable Companies
CRVO CRBU STRO SAVA TELO JSPR MNOV ZIVO UNCY AURX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N2U0:Germany
Address
685 US Highway 1, New Jersey Biotechnology Development Center, 2nd floor, North Brunswick, NJ, USA, 08902
Website
https://www.adlainortye.com
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.